Damora Therapeutics

DMRA · NASDAQ

$20.67+$1.40 (+7.27%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $19.27

DMRA analyst rating

BuyConsensus of 6 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy6
Hold0
Underperform0
Sell0

12-month price target · 11 analysts

Average $47.83 (+131.4% upside)

Low: $40.40
Now: $20.67
High: $63.00

Upgrades and downgrades

The latest rating actions, newest first

DMRA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wedbush	Sep 29, 2026	Maintains	Outperform	$40.00	46%
Guggenheim	Sep 25, 2026	Maintains	Buy	$40.00 → $60.00	46%
Wedbush	Jul 30, 2026	Maintains	Outperform	$35.00 → $40.00	46%
Jefferies	Jul 27, 2026	Initiates	Buy	$50.00	45%
HC Wainwright & Co.	Jul 21, 2026	Maintains	Buy	$45.00	32%
Wedbush	Jun 12, 2026	Maintains	Outperform	$35.00	46%
HC Wainwright & Co.	Jun 11, 2026	Initiates	Buy	$45.00	32%
Wedbush	May 28, 2026	Initiates	Outperform	$35.00	46%
RBC Capital	Apr 24, 2026	Initiates	Outperform	$40.00	44%
Evercore ISI Group	Mar 25, 2026	Initiates	Outperform	$46.00	42%

The case for and against

Updated Oct 17, 2026

Bull case

Damora Therapeutics is attractive because DMR-001 targets a highly underserved mutant calreticulin market in ET and MF with a potentially subtype-agnostic profile, including activity across Type 1 and Type 2 mutations and a projected once-monthly subcutaneous autoinjector that could be more convenient than competing Q2W IV or on-body approaches. The company also appears financially de-risked, with $540.5MM in cash and equivalents at the end of 2Q26 expected to fund operations into 2H29, covering the mid-2027 proof-of-concept readouts and potentially the start of Phase 3 as early as mid-2028. Beyond DMR-001, DMR-002 and DMR-003 provide additional shots on goal, while the broader anti-mutCALR franchise could benefit from emerging regulatory precedent and the clinical case for earlier intervention in myelofibrosis.

Bear case

Damora Therapeutics is facing a structurally difficult competitive setup, as INCA033989 appears to hold a 2-3 year head start over DMR-001, raising the risk that the addressable mutCALR population is captured before Damora can generate meaningful clinical data. Execution risk is also elevated because IND delays, SC manufacturing issues, slower Ph 1 enrollment, or additional IND-enabling requests could push the POC readout beyond mid-2027, extending the pre-revenue period and limiting investor confidence. Fundamentally, the company is targeting a market where Jakafi’s safety and persistence shortcomings create opportunity, but that does not offset the chance that DMR-001 is late, less efficacious, or faces unforeseen safety issues in a field with new competitors emerging.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.